Array BioPharma Inc. (NASDAQ:ARRY) will report financial results for the second quarter of fiscal 2012 on Monday, January 30, 2012, and will hold a conference call on Tuesday, January 31, 2012 at 9:00 a.m. eastern time to discuss these results. Michael Carruthers, Chief Financial Officer, and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.

Conference Call Information

Date:

   Tuesday, January 31, 2012

Time:

 9:00 a.m. eastern time

Toll-Free:

 800.599.9816

Toll:

 617.847.8705

Pass Code:

 50624264

Webcast & Conference Call Slides:

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

 

A replay of the call will be available as a webcast on www.arraybiopharma.com.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com